Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label lucitanib monotherapy in ER-positive metastatic breast cancer
2013-000288-10Phase 2Completed
- Sponsor
- Servier
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of lucitanib in breast cancer (3 cohorts), sponsored by Servier. Primary endpoint: Objective response rate (ORR). Started Jun 2013; status: completed.
02
Drugs
lucitanib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-000288-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000288-10.